Eicosapentaenoic Acid (Synonyms: Single-Use EPA (peroxide free), Single-Use Timnodonic Acid (peroxide free)) |
Catalog No.GC11344
One-Click Copy Product Info
|
Eicosapentaenoic Acid (EPA) is an orally active omega-3 (ω-3) long-chain polyunsaturated fatty acid (PUFA) and a precursor to prostaglandin-3, thromboxane-3, and leukotriene-5 eicosanoids.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 10417-94-4
Sample solution is provided at 25 µL, 10mM.
Eicosapentaenoic Acid (EPA) is an orally active omega-3 (ω-3) long-chain polyunsaturated fatty acid (PUFA) and a precursor to prostaglandin-3, thromboxane-3, and leukotriene-5 eicosanoids[1]. Eicosapentaenoic Acid has anti-inflammatory, anti-cardiovascular disease, and anti-diabetic effects. It is found in large quantities in marine organisms[2, 3].
In vitro, Eicosapentaenoic Acid (100 µM) significantly reduces the level of the inflammatory cytokine IL-8 in MDA-MB-231 and MCF-7 breast cancer cells after 48 hours of treatment [4]. Eicosapentaenoic Acid (0.1 μM, 1 μM, 10 μM) induces apoptosis in a dose-dependent manner and activates caspase-3, -7, -9, and PARP enzymes in TE11 and KYSE180 esophageal cancer cells after 24 hours of treatment [5]. Eicosapentaenoic Acid (25 μM) significantly inhibits the proliferation of HT-29 colon cancer cells and downregulates the PI-3K/Akt/mTOR signaling pathway after 24 hours of treatment [6].
In vivo, Eicosapentaenoic Acid (500 mg/kg) administered orally to type 2 diabetic Goto-Kakizaki rats for 4 weeks, significantly reduces circulating insulin levels by 48%, and increases GLUT4 mRNA content in skeletal muscle and adipose tissue [7].
References:
[1] Mason R P, Libby P, Bhatt D L. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid[J]. Arteriosclerosis, thrombosis, and vascular biology, 2020, 40(5): 1135-1147.
[2] Šimat V, Elabed N, Kulawik P, et al. Recent advances in marine-based nutraceuticals and their health benefits[J]. Marine drugs, 2020, 18(12): 627.
[3] Nobre M E P, Correia A O, de Brito Borges M, et al. Eicosapentaenoic acid and docosahexaenoic acid exert anti-inflammatory and antinociceptive effects in rodents at low doses[J]. Nutrition research, 2013, 33(5): 422-433.
[4] Rasha F, Kahathuduwa C, Ramalingam L, et al. Combined effects of eicosapentaenoic acid and adipocyte renin–angiotensin system inhibition on breast cancer cell inflammation and migration[J]. Cancers, 2020, 12(1): 220.
[5] Mizoguchi K, Ishiguro H, Kimura M, et al. Induction of apoptosis by eicosapentaenoic acid in esophageal squamous cell carcinoma[J]. Anticancer research, 2014, 34(12): 7145-7149.
[6] Tang F Y, Cho H J, Pai M H, et al. Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells[J]. The Journal of nutritional biochemistry, 2009, 20(6): 426-434.
[7] Figueras M, Olivan M, Busquets S, et al. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status[J]. Obesity, 2011, 19(2): 362-369.
| Cell experiment [1]: | |
|
Cell lines |
MDA-MB-231、MCF-7 cells |
|
Preparation Method |
MDA-MB-231 and MCF-7 cells were treated with 100 µM of Eicosapentaenoic Acid for 48 h. |
|
Reaction Conditions |
100 µM; 48h |
|
Applications |
Eicosapentaenoic Acid treatment significantly reduced the level of IL-8 in cells. |
| Animal experiment [2]: | |
|
Animal models |
Male 3-week-old Goto-Kakizaki rats |
|
Preparation Method |
Male 3-week-old Goto-Kakizaki rats were used. This is a rat model with spontaneous type 2 diabetes. The animals were maintained on a regular light-dark cycle at an ambient temperature and had free access to food and water. Rats were divided into one of three groups: control, Eicosapentaenoic Acid (EPA) and linoleic acid (LINO), respectively. EPA group: animals fed the same as control but supplemented daily with 500mg/kg body weight of EPA mixed in carboxymethylcellulose 1% given by a single gavage. The treatment took place for 4 weeks before the animals were killed. |
|
Dosage form |
500mg/kg; p.o. |
|
Applications |
Administration of Eicosapentaenoic Acid resulted in a significant decrease in circulating insulin (48%), this was not observed in the LINO group. Eicosapentaenoic Acid resulted in an increased GLUT4 mRNA content in both skeletal muscle and adipose tissue. |
|
References: |
|
| Cas No. | 10417-94-4 | SDF | |
| Synonyms | Single-Use EPA (peroxide free), Single-Use Timnodonic Acid (peroxide free) | ||
| Chemical Name | (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid | ||
| Canonical SMILES | CC/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\C/C([H])=C([H])\CCCC(O)=O | ||
| Formula | C20H30O2 | M.Wt | 302.45 |
| Solubility | ≥ 116.8mg/mL in DMSO | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3063 mL | 16.5317 mL | 33.0633 mL |
| 5 mM | 661.3 μL | 3.3063 mL | 6.6127 mL |
| 10 mM | 330.6 μL | 1.6532 mL | 3.3063 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)